A cohort analysis of 53 severely ill hospitalized COVID-19 patients who received Gilead Sciences’ (NASDAQ:GILD) antiviral remdesivir on a compassionate use basis showed a treatment benefit. The data were just published in the New England Journal of Medicine.
64% (n=34/53) of patients were on mechanical ventilation at baseline, including four also on extracorporeal membrane oxygenation (blood is circulated through an artificial lung to oxygenate).
68% of patients receiving remdesivir experienced
an improvement in oxygen support class over median follow-up of 18 days.
57% (n=17/30) of those on mechanical ventilation were extubated and 47%
(25/53) of the total group were discharged from the hospital.
After 28 days of follow-up, the cumulative
incidence of clinical improvement was 84% (discharge from hospital
and/or at least a two-point improvement from baseline in predefined
six-point scale).
The overall mortality rate was 13% (n=7/53), lower than 18% (n=6/34) in a subgroup of patients on invasive ventilation.
No new safety signals were observed.
Two Phase 3 studies are in process with topline data from one, SIMPLE, expected this month.
A China-based study in severely ill COVID-19
patients has been terminated due to low enrollment while another in
mild-to-moderately ill patients in ongoing.
More than 1,800 patients have received remdesivir to date.
https://seekingalpha.com/news/3559945-gileads-remdesivir-shows-positive-effect-in-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.